个股
共 6,277 份研报 · 国内 4,018 · 国外 1,840
ESMO摘要:G12D('734)具备竞争实力,关注会议获取'890更多细节;两者的更成熟数据即将公布
ESMO Abstracts: G12D ('734) In the Hunt, Look to Mtg For Add'l Detail on '890; More Mature Data for Both Coming Soon
摩根大通·2026-10-19·9 页·美股
武田制药(4502):ESMO 2026摘要:TAK-928作为一线非小细胞肺癌治疗的良好补充数据;焦点转向与竞争对手依沃西单抗的差异化
武田制药 (4502): ESMO 2026 abstract: Good additional data on TAK-928 as first-line NSCLC treatment; focus now on differentiation with competitor ivonescimab
摩根大通·2026-10-19·11 页·其它
维多利亚的秘密(VSXY.US):高管视野:"天使降临";管理层交流与实地调研;上调盈利预测并维持110美元目标价
Victoria's Secret (VSXY): Boss' Eye: "The Angels Have Landed"; Mgmt Access & Fieldwork; Raising #'s w/ $110 PT
摩根大通·2026-10-19·14 页·美股
托尔兄弟(TOL):基于相对价值上调至增持——相比入门级住宅建筑商更青睐高端住宅
Toll Brothers: Upgrading to Overweight on Relative Value - Prefer Luxury to Entry-Level Homebuilders
摩根大通·2026-10-19·8 页·美股
美国钢铁(X):新投资级担保债券具吸引力,评级上调至增持
United States Steel (X): Upgrading to Overweight as New IG-Rated Guaranteed Bonds Look Attractive
摩根大通·2026-10-19·8 页·美股
吉利德科学(GILD.US):溃疡性结肠炎口服A4B7数据前景广阔
Gilead Sciences (GILD): Promising Oral A4B7 Data In UC
摩根大通·2026-10-19·9 页·美股
保诚(PRU.L)2026年第三季度新业务价值前瞻:2026年前三季度NBP预计增长7%,全年双位数增长仍可期——在此估值下不知为何还要关注
Prudential Plc (PRU.L): 3Q26E Preview: 7% NBP growth in 9M26E, double-digit still in sight for FY26E — not sure why we care at this valuation
摩根大通·2026-10-19·15 页·其它
安费诺(APH.US)2026年第三季度前瞻:AI与非AI业务上行支撑业绩超预期并上调指引,下半年股价有望跑赢大市;重申增持
Amphenol (APH): 3Q26 Preview: AI and Non-AI Upside Set to Support Beat and Raise and 2H26 Share Outperformance; Reit. OW
摩根大通·2026-10-19·13 页·美股
艾伯维(ABBV.US):Skyrizi与α4β7联合疗法疗效稳健,有望提高克罗恩病治疗标准
AbbVie (ABBV.US): Solid Skyrizi/α4β7 Combo Efficacy Should Raise The Bar in Crohn's Disease
摩根大通·2026-10-19·9 页·美股
X-energy(XE.US):持续推动商业化落地,与美国电力公司及亚马逊签署960兆瓦联合开发协议
X-energy (XE): XE Continues Commercial Execution, Inking JDA with AEP and Amazon for 960MW
摩根大通·2026-10-19·8 页·美股
EyePoint(EYPT.US):湿性AMD遭遇两次挫折后评级下调至低配
摩根大通·2026-10-19·10 页·美股
BeOne – ADR:ESMO摘要巩固实体瘤研发管线潜力
BeOne – ADR: ESMO Abstracts Reinforce Solid Tumor Pipeline Potential
摩根大通·2026-10-19·9 页·美股
招金矿业(1818.HK):持有——复苏延迟,预期下调
Zhaojin Mining (1818 HK): Hold: Delayed recovery, lower expectations
汇丰银行·2026-10-19·8 页·港股
恒隆地产(0101.HK)买入:项目实地调研核心纪要
恒隆地产 (0101.HK): Hang Lung Properties (101 HK) Buy: Key takeaways from project visits
汇丰银行·2026-10-19·8 页·港股
股票速览:South32有限公司——27财年第一季度经营业绩:铜产量低于预期
South32 Limited (S32 LN): 1Q27 operational results: Copper production lower than expectations
汇丰银行·2026-10-19·7 页·其它
英特格(ENTG.O):9月季度业绩与投资者日前瞻
Entegris Inc (ENTG.O) Sep-Q + Investor Day Preview
花旗·2026-10-19·16 页·美股
礼来(LLY.N):小儿溃疡性结肠炎数据为Omvoh增长开辟新途径
Eli Lilly (LLY.N): Pediatric ulcerative colitis data add another avenue for Omvoh growth
花旗·2026-10-19·11 页·美股
高知特(CTSH.O):关注第四季度营收爬坡
Cognizant Technology Solution Corp. (CTSH.O): Watching 4Q26 Revenue Ramp
花旗·2026-10-19·16 页·美股
必和必拓(BHP.AX,BHP.L):铜产量季度疲软被实现价格抵消,指引维持不变:中性
BHP Ltd (BHP.AX, BHP.L): Weak Copper Quarter offset by Realised Prices, Guidance Unchanged: Neutral
花旗·2026-10-19·17 页·其它
百济神州(ONC.O):ESMO摘要显示实体瘤管线全面进展(PRMT5i、CEA ADC、GPC3x4-1BB双抗及CDK4i)
BeOne Medicines (ONC.O): ESMO Abstracts Highlight Progress Across Solid Tumor Pipeline (PRMT5i, CEA ADC, GPC3x4-1BB bispecific, and CDK4i)
花旗·2026-10-19·14 页·美股
显示 3841 - 3860 条,共 6,277 条